Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori
Clicks: 326
ID: 118653
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
326 views
62 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #5 of 7 articles by views in oncology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Introduction: Clarithromycin (CAM)-based triple therapy comprising proton pump inhibitors and amoxicillin is administered as first-line eradication treatment against Helicobacter pylori infection. However, the eradication rate achieved with CAM-based triple therapy has decreased to H. pylori eradication. Methods:H. pylori-positive patients were tre
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (43 words).
Try re-searching for a better abstract.
| Reference Key |
adachi2017oncologycomparative
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Teppei Adachi;Shigenaga Matsui;Tomohiro Watanabe;Kazuki Okamoto;Ayana Okamoto;Masashi Kono;Mitsunari Yamada;Tomoyuki Nagai;Yoriaki Komeda;Kosuke Minaga;Ken Kamata;Kentaro Yamao;Mamoru Takenaka;Yutaka Asakuma;Toshiharu Sakurai;Naoshi Nishida;Hiroshi Kashida;Masatoshi Kudo; |
| Journal | oncology |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.